AstraZeneca announced that its breast cancer drug, Truqap, in combination with chemotherapy agent, paclitaxel, did not meet its main goals in a late-stage trial to improve overall survival of patients with a type of breast cancer on June 18, 2024.
The trial, known as CAPItello-290, was testing whether the drug combination improved overall survival in patients with inoperable or metastatic triple-negative breast cancer versus the older and cheaper chemotherapy agent, paclitaxel, in combination with a placebo.
The study failed to achieve its goals in both the overall trial population and in a sub-group of patients with tumours harbouring specific biomarker alterations, the drugmaker said.
“While we are disappointed in the CAPItello-290 outcome, these results will further our understanding of the role of the PI3K/AKT pathway in breast cancer,” said Susan Galbraith, executive vice president, oncology R&D, AstraZeneca.
The post appeared first on .